Monte Rosa Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Monte Rosa Therapeutics (GLUE).

Price Target Range — 10 Quarters

Analyst Consensus — 8 Analysts

8Buy

Consensus RatingOverweight# Analysts8Avg. Consensus PT$26Upside to Avg. PT+141.1%

Rating Trend — Last 9 Months

Recent Analyst Actions

すべての評価を見る →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 12, 2026	UBS	Alice Nettleton	Assumes	Buy	$17→$19
Oct 5, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	Maintained	Buy	$25
Oct 1, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	Initiate	Buy	$25
Sep 9, 2026	Wedbush	Robert Driscoll	Maintained	Outperform	$27
Aug 25, 2026	Guggenheim	Michael Schmidt	Maintained	Buy	$28
Aug 7, 2026	JP Morgan	Brian Cheng	PT Cut	Overweight	$31→$27
Aug 7, 2026	Guggenheim	Michael Schmidt	PT Cut	Buy	$35→$28
Aug 7, 2026	Wells Fargo	Derek Archila	PT Cut	Overweight	$29→$27
Aug 3, 2026	Wedbush	Robert Driscoll	PT Cut	Outperform	$37→$27
Jun 30, 2026	Guggenheim	Michael Schmidt	PT Raise	Buy	$30→$35
May 11, 2026	JP Morgan	Brian Cheng	PT Raise	Overweight	$30→$31
Mar 18, 2026	Guggenheim	Michael Schmidt	PT Cut	Buy	$34→$30
Mar 18, 2026	Wells Fargo	Derek Archila	PT Cut	Overweight	$30→$29
Jan 14, 2026	Piper Sandler	Edward Tenthoff	PT Raise	Overweight	$28→$37
Jan 8, 2026	Wells Fargo	Derek Archila	PT Raise	Overweight	$22→$30
Jan 8, 2026	Guggenheim	Michael Schmidt	PT Raise	Buy	$16→$34
Dec 16, 2025	Wells Fargo	Derek Archila	Upgrade	Equal-Weight→Overweight	$13→$22
Nov 7, 2025	Wells Fargo	Derek Archila	PT Raise	Equal-Weight	$10→$13
Mar 21, 2025	Wells Fargo	Derek Archila	PT Cut	Equal-Weight	$11→$10
Mar 21, 2025	Wedbush	Robert Driscoll	PT Raise	Outperform	$15→$17

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on Monte Rosa Therapeutics, Maintains $25 Price Target

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Monte Rosa Therapeutics (NASDAQ:GLUE) with a Buy and maintains $25 price target.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Initiates Coverage On Monte Rosa Therapeutics with Buy Rating, Announces Price Target of $25

HC Wainwright & Co. analyst Mitchell S. Kapoor initiates coverage on Monte Rosa Therapeutics (NASDAQ:GLUE) with a Buy rating and announces Price Target of $25.

Benzinga Newsdesk

PRO
Wedbush Reiterates Outperform on Monte Rosa Therapeutics, Maintains $27 Price Target

Wedbush analyst Robert Driscoll reiterates Monte Rosa Therapeutics (NASDAQ:GLUE) with a Outperform and maintains $27 price target.

Benzinga Newsdesk

PRO
Guggenheim Reiterates Buy on Monte Rosa Therapeutics, Maintains $28 Price Target

Guggenheim analyst Michael Schmidt reiterates Monte Rosa Therapeutics (NASDAQ:GLUE) with a Buy and maintains $28 price target.

Benzinga Newsdesk

PRO
JP Morgan Maintains Overweight on Monte Rosa Therapeutics, Lowers Price Target to $27

JP Morgan analyst Brian Cheng maintains Monte Rosa Therapeutics (NASDAQ:GLUE) with a Overweight and lowers the price target from $31 to $27.

Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on Monte Rosa Therapeutics, Lowers Price Target to $28

Guggenheim analyst Michael Schmidt maintains Monte Rosa Therapeutics (NASDAQ:GLUE) with a Buy and lowers the price target from $35 to $28.

Benzinga Newsdesk

Monte Rosa Therapeutics Inc

ニュース

パートナーシップ

ベンジンガ・グローバル

Monte Rosa Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on Monte Rosa Therapeutics, Maintains $25 Price Target

PRO
HC Wainwright & Co. Initiates Coverage On Monte Rosa Therapeutics with Buy Rating, Announces Price Target of $25

PRO
Wedbush Reiterates Outperform on Monte Rosa Therapeutics, Maintains $27 Price Target

PRO
Guggenheim Reiterates Buy on Monte Rosa Therapeutics, Maintains $28 Price Target

PRO
JP Morgan Maintains Overweight on Monte Rosa Therapeutics, Lowers Price Target to $27

PRO
Guggenheim Maintains Buy on Monte Rosa Therapeutics, Lowers Price Target to $28

People Also Watch

People Also Watch

Monte Rosa Therapeutics Inc

ニュース

パートナーシップ

ベンジンガ・グローバル

Monte Rosa Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROHC Wainwright & Co. Reiterates Buy on Monte Rosa Therapeutics, Maintains $25 Price Target

PROHC Wainwright & Co. Initiates Coverage On Monte Rosa Therapeutics with Buy Rating, Announces Price Target of $25

PROWedbush Reiterates Outperform on Monte Rosa Therapeutics, Maintains $27 Price Target

PROGuggenheim Reiterates Buy on Monte Rosa Therapeutics, Maintains $28 Price Target

PROJP Morgan Maintains Overweight on Monte Rosa Therapeutics, Lowers Price Target to $27

PROGuggenheim Maintains Buy on Monte Rosa Therapeutics, Lowers Price Target to $28

People Also Watch

People Also Watch

PRO
HC Wainwright & Co. Reiterates Buy on Monte Rosa Therapeutics, Maintains $25 Price Target

PRO
HC Wainwright & Co. Initiates Coverage On Monte Rosa Therapeutics with Buy Rating, Announces Price Target of $25

PRO
Wedbush Reiterates Outperform on Monte Rosa Therapeutics, Maintains $27 Price Target

PRO
Guggenheim Reiterates Buy on Monte Rosa Therapeutics, Maintains $28 Price Target

PRO
JP Morgan Maintains Overweight on Monte Rosa Therapeutics, Lowers Price Target to $27

PRO
Guggenheim Maintains Buy on Monte Rosa Therapeutics, Lowers Price Target to $28